Price Alert

Deciphera Pharmaceuticals... (DCPH)

NASDAQ: DCPH · Real-Time Price · USD

25.59

0.02 (0.08%)

At close: Jun 10, 2024, 10:00 PM

Deciphera Pharmaceuticals Statistics

Share Statistics

Deciphera Pharmaceuticals has 86.48M shares outstanding. The number of shares has increased by 0% in one year.

Shares Outstanding	86.48M
Shares Change (YoY)	0%
Shares Change (QoQ)	0%
Owned by Institutions (%)	n/a
Shares Floating	46.43M
Failed to Deliver (FTD) Shares	1,305
FTD / Avg. Volume	0.07%

Short Selling Information

The latest short interest is 3.17M, so 3.67% of the outstanding shares have been sold short.

Short Interest	3.17M
Short % of Shares Out	3.67%
Short % of Float	5.12%
Short Ratio (days to cover)	2.79

Valuation Ratios

The PE ratio is -7.04 and the forward PE ratio is -44.12. Deciphera Pharmaceuticals's PEG ratio is 2.09.

PE Ratio	-7.04
Forward PE	-44.12
PS Ratio	8.4
Forward PS	5.8
PB Ratio	3.91
P/FCF Ratio	-9.3
PEG Ratio	2.09

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Deciphera Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.8, with a Debt / Equity ratio of 0.07.

Current Ratio	3.8
Quick Ratio	3.59
Debt / Equity	0.07
Debt / EBITDA	-0.12
Debt / FCF	-0.18
Interest Coverage	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$460.16K
Profits Per Employee	$-549.13K
Employee Count	355
Asset Turnover	0.34
Inventory Turnover	0.18

Taxes

Income Tax	431K
Effective Tax Rate	-0.22%

Stock Price Statistics

The stock price has increased by 0% in the last 52 weeks. The beta is 0.18, so Deciphera Pharmaceuticals's price volatility has been higher than the market average.

Beta	0.18
52-Week Price Change	n/a
50-Day Moving Average	21.46
200-Day Moving Average	15.86
Relative Strength Index (RSI)	85.58
Average Volume (20 Days)	1,855,995

Income Statement

In the last 12 months, Deciphera Pharmaceuticals had revenue of 163.36M and earned -194.94M in profits. Earnings per share was -2.29.

Revenue	163.36M
Gross Profit	159.62M
Operating Income	-210.96M
Net Income	-194.94M
EBITDA	-208.86M
EBIT	-210.96M
Earnings Per Share (EPS)	-2.29

Full Income Statement

Balance Sheet

The company has 83.51M in cash and 25.88M in debt, giving a net cash position of 57.63M.

Cash & Cash Equivalents	83.51M
Total Debt	25.88M
Net Cash	57.63M
Retained Earnings	-1.43B
Total Assets	420.93M
Working Capital	266.51M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -146.7M and capital expenditures -778K, giving a free cash flow of -147.47M.

Operating Cash Flow	-146.7M
Capital Expenditures	-778K
Free Cash Flow	-147.47M
FCF Per Share	-1.73

Full Cash Flow Statement

Margins

Gross margin is 97.72%, with operating and profit margins of -129.14% and -119.34%.

Gross Margin	97.72%
Operating Margin	-129.14%
Pretax Margin	-119.07%
Profit Margin	-119.34%
EBITDA Margin	-127.85%
EBIT Margin	-129.14%
FCF Margin	-90.28%

Dividends & Yields

DCPH does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

Currently there are no analyst rating for DCPH.

Price Target	$25.6
Price Target Difference	0%
Analyst Consensus	Hold
Analyst Count	5

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	7.31
Piotroski F-Score	3